Skip to content
Evigrade
CriticalClass Ia antiarrhythmic with antimuscarinic activity×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Disopyramide, a class IA antiarrhythmic, can prolong the QT interval and cause ventricular arrhythmias, including torsade de pointes (disopyramide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). No studies have looked at ziprasidone together with other QT-prolonging drugs, and an additive effect cannot be excluded (ziprasidone SmPC, AEMPS). CYP3A metabolises disopyramide. Ziprasidone is cleared mainly through reduction by glutathione and aldehyde oxidase, and less than one third of its clearance goes through cytochrome P450 enzymes (disopyramide SmPC, AEMPS; ziprasidone label, FDA). Ziprasidone is unlikely to change the metabolism of other drugs to a clinically relevant degree. The documents give no data on how disopyramide affects ziprasidone levels (ziprasidone SmPC, AEMPS, and label, FDA).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Like all antiarrhythmics, disopyramide can worsen an arrhythmia or cause a new one (ventricular tachycardia, ventricular fibrillation or torsade de pointes). On the ECG it can cause QT prolongation, QRS widening, atrioventricular block and bundle branch block (disopyramide SmPC, AEMPS). Arrhythmias caused by disopyramide are more likely with low potassium, severe structural heart disease, a prolonged QT interval and use with other antiarrhythmics (disopyramide SmPC, AEMPS). In people taking QT-prolonging drugs, a slow heart rate, low potassium or magnesium, and the use of other such drugs raise the risk of torsade de pointes and sudden death (ziprasidone label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated under the Spanish ziprasidone summaries of product characteristics (SmPCs), for both the originator and the generic. They contraindicate ziprasidone with QT-prolonging drugs and explicitly name class IA antiarrhythmics among them. The disopyramide SmPC places disopyramide in this class (ziprasidone and disopyramide SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The disopyramide SmPC also contraindicates its use with other antiarrhythmics or with drugs that may cause ventricular arrhythmias, especially torsades de pointes (disopyramide SmPC, AEMPS). The Spanish SmPC also contraindicates ziprasidone in arrhythmias treated with class IA and III antiarrhythmics. The US label contraindicates it with class Ia and III antiarrhythmics as well (ziprasidone SmPC, AEMPS; ziprasidone label, US Food and Drug Administration, FDA). Ziprasidone is also contraindicated in known QT prolongation, recent acute myocardial infarction and decompensated heart failure. Disopyramide is contraindicated in pre-existing QT prolongation, untreated second- or third-degree atrioventricular block, severe sinus node dysfunction, decompensated heart failure and cardiogenic shock (ziprasidone and disopyramide SmPCs, AEMPS). Correct low potassium and magnesium before starting ziprasidone (ziprasidone SmPC, AEMPS). Correct potassium disturbances before starting disopyramide (disopyramide label, FDA). During disopyramide treatment, monitor blood potassium and correct it if needed (disopyramide SmPC, AEMPS). During disopyramide treatment, also monitor the QT interval and QRS duration, and stop disopyramide if they lengthen by more than 25% (disopyramide SmPC, AEMPS). If palpitations, vertigo, fainting or seizures appear during ziprasidone treatment, carry out a cardiac assessment including an electrocardiogram (ECG). If the heart-rate-corrected QT interval (QTc) exceeds 500 ms, the SmPC recommends interrupting ziprasidone (ziprasidone SmPC, AEMPS). No document gives an interval between stopping one drug and starting the other. The half-life of disopyramide is 4.4–8.2 hours in healthy people and longer in renal, hepatic and heart failure. The mean half-life of oral ziprasidone is 6.6 hours (disopyramide and ziprasidone SmPCs, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Disopyramide

Other interactions with Ziprasidone